← Oncology Approval Tracker

FDA DECISION ·

Bynfezia Pen

octreotide acetate · Sun Pharmaceutical Industries

FDA approvalNew formulationCarcinoid syndrome and VIPoma-associated diarrhea
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Subcutaneous octreotide pen for adults with severe diarrhea or flushing associated with metastatic carcinoid tumors, or profuse watery diarrhea due to VIP-secreting tumors.

LAMPGEN ANALYSIS

Why it matters

This was the pen’s initial authorization for the labeled tumor-related symptoms. FDA later rescinded the original approval and reapproved the pen in 2024.

What research teams should watch

Track the product and presentation in medication records and verify that patients have received training on pen dosing and disposal.

PRIMARY RECORDS

Sources